1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Vulvar Cancer Global Clinical Trials Review, H1, 2014

Vulvar Cancer Global Clinical Trials Review, H1, 2014

  • April 2014
  • -
  • Global Data
  • -
  • 85 pages

Vulvar Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Vulvar Cancer Global Clinical Trials Review, H1, 2014" provides data on the Vulvar Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vulvar Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Vulvar Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Vulvar Cancer Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Vulvar Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Vulvar Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Vulvar Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Vulvar Cancer 24
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Vulvar Cancer Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Vulvar Cancer 31
Nov 05, 2009: ISA Pharmaceuticals Announces NEJM Publication On VIN Phase II Data 31
Apr 21, 2008: Graceway Pharmaceuticals Reports Study in New England Journal of Medicine: Aldara (imiquimod) Cream, 5% demonstrated a reduction in lesion size in patients with vulvar intraepithelial neoplasia (VIN). 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Merck and Co., Inc. 32
Clinical Trial Overview of Merck and Co., Inc. 32
ISA Pharmaceuticals B.V. 33
Clinical Trial Overview of ISA Pharmaceuticals B.V. 33
Precision Therapeutics, Inc. 34
Clinical Trial Overview of Precision Therapeutics, Inc. 34
GlaxoSmithKline plc 35
Clinical Trial Overview of GlaxoSmithKline plc 35
Burzynski Research Institute, Inc. 36
Clinical Trial Overview of Burzynski Research Institute, Inc. 36
Clinical Trial Overview of Top Institutes / Government 37
National Cancer Institute 37
Clinical Trial Overview of National Cancer Institute 37
Gynecologic Oncology Group 39
Clinical Trial Overview of Gynecologic Oncology Group 39
Case Comprehensive Cancer Center 40
Clinical Trial Overview of Case Comprehensive Cancer Center 40
The University of Texas M. D. Anderson Cancer Center 41
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 41
Women and Infants Hospital of Rhode Island 42
Clinical Trial Overview of Women and Infants Hospital of Rhode Island 42
Leiden University Medical Center 43
Clinical Trial Overview of Leiden University Medical Center 43
Northwestern University 44
Clinical Trial Overview of Northwestern University 44
Memorial Sloan Kettering Cancer Center 45
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 45
Erasmus MC 46
Clinical Trial Overview of Erasmus MC 46
Five Key Clinical Profiles 47
Appendix 82
Abbreviations 82
Definitions 82
Research Methodology 83
Secondary Research 83
About GlobalData 84
Contact Us 84
Disclaimer 84
Source 85

List of Tables
Vulvar Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Vulvar Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Vulvar Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Vulvar Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Vulvar Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Vulvar Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Vulvar Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Vulvar Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Vulvar Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Vulvar Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Vulvar Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Vulvar Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Vulvar Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Vulvar Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Vulvar Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Vulvar Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Vulvar Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Vulvar Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Vulvar Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 24
Vulvar Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Vulvar Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Vulvar Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Vulvar Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Vulvar Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Vulvar Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 32
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by ISA Pharmaceuticals B.V., 2014* 33
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Precision Therapeutics, Inc., 2014* 34
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 35
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Burzynski Research Institute, Inc., 2014* 36
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 37
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Gynecologic Oncology Group, 2014* 39
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 40
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 41
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Women and Infants Hospital of Rhode Island, 2014* 42
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 43
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2014* 44
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 45
Vulvar Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2014* 46

List of Figures
Vulvar Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Vulvar Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Vulvar Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Vulvar Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Vulvar Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Vulvar Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Vulvar Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Vulvar Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Vulvar Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Vulvar Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Vulvar Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Vulvar Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Vulvar Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Vulvar Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Vulvar Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Vulvar Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Vulvar Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Vulvar Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Vulvar Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Vulvar Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Vulvar Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 83

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.